

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): April 1, 2014**

---

**TECHNE CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

---

**Minnesota**  
(State or Other Jurisdiction  
of Incorporation)

**0-17272**  
(Commission  
File Number)

**41-1427402**  
(I.R.S. Employer  
Identification Number)

**614 McKinley Place NE**  
**Minneapolis, MN**  
(Address of Principal Executive Offices)

**55413**  
(Zip Code)

**(612) 379-8854**  
(Registrant's Telephone Number, Including Area Code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 1.01 Entry Into a Material Definitive Agreement.**

On April 1, 2014, Techne Corporation (the “Company”), Research and Diagnostic Systems, Inc. (“R&D”), a Minnesota corporation and wholly-owned subsidiary of the Company, and Cayenne Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly-owned subsidiary of R&D, entered into an Agreement of Investment and Merger (the “Agreement”) with CyVek, Inc., a Delaware corporation (“CyVek”), and Citron Capital Limited, as Stockholders’ Agent. Pursuant to the terms of the Agreement, on April 2, 2014, R&D invested \$10 million in CyVek and received shares of Common Stock representing 19.99% of the outstanding voting stock of CyVek. In connection with this investment, R&D became a party to CyVek’s existing investor agreements and will have an observer seat on CyVek’s Board of Directors.

If, within 12 months of the date of the Agreement (subject to a 90 day extension in the discretion of R&D), CyVek meets commercial milestones related to the sale, lease or license of its CyPlex analyzer product to at least 10 separate customers and the sale of at least 500 of its CyPlex cartridges, R&D will acquire CyVek through the merger of Merger Sub with and into CyVek, with CyVek surviving the merger as a wholly-owned subsidiary of R&D (the “Merger”). The Merger is also contingent upon the accuracy of certain representations and warranties of the parties as of the date of the Merger and other customary closing conditions. The stockholders of CyVek have approved the Merger, and certain stockholders of CyVek have executed agreements to continue to support the Merger and granted proxies to R&D to vote their shares in favor of the Merger and against alternative proposals.

If the Merger is consummated, R&D will make an initial payment of \$60 million to the other stockholders of CyVek, of which \$6 million will be placed in escrow for 15 months to secure indemnity obligations of such stockholders. The purchase price payable at the closing of the Merger may be adjusted based on the final levels of cash, indebtedness and transaction expenses of CyVek as of the closing. R&D will also pay CyVek’s other stockholders up to \$35 million based on the revenue generated by CyVek’s products and related products before the date that is 30 months from the closing of the Merger, subject to acceleration upon certain change of control and breach of covenant events. R&D will also pay CyVek’s other stockholders 50% of the amount, if any, by which the revenue from CyVek’s products and related products exceeds \$100 million in calendar year 2020. Techne and R&D will be subject to certain restrictions on the transfer of the business acquired from CyVek and related assets until January 1, 2021.

Certain CyVek stockholders will be subject to non-solicitation obligations for three years following the closing of the Merger and non-compete obligations for five years following the closing of the Merger.

This description of the material terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending June 30, 2014.

A copy of the press release announcing the investment is filed herewith as Exhibit 99.1.

---

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release, dated April 4, 2014.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TECHNE CORPORATION

Date: April 4, 2014

By: /s/ Charles R. Kummeth

Charles R. Kummeth  
President and Chief Executive Officer

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated April 4, 2014.

## BIO-TECHNE ANNOUNCES INVESTMENT IN CYVEK, INC.

Minneapolis/ April 4, 2014/ Techne Corporation (NASDAQ: TECH), d/b/a Bio-Techne, announced today that it has made a \$10 million equity investment in CyVek, Inc. (CyVek), with a commitment to acquire CyVek if certain future milestones are met.

CyVek has developed a transformative immunoassay technology, CyPlex™, which integrates an innovatively designed microfluidic cartridge with a state-of-the-art analyzer to deliver the most advanced and efficient bench top immunoassay system. CyPlex's™ ability to provide "sample to answer" test results precisely and quickly in a sealed disposable device makes it a very attractive platform for clinical applications. The CyPlex™ technology has demonstrated broad applicability across numerous sectors, including routine life sciences research applications. Commercial launch will be initially targeted towards customers who focus on translational research where sensitive, precise, accurate, multi-analyte results from small sample volumes are highly critical.

"CyVek has succeeded in developing a technology that combines unrivaled ease-of-use with extraordinary precision. With its legacy as the world's most thoroughly characterized antibody company, Bio-Techne has antibodies and reagents that are a perfect complement to the CyPlex™ platform. The combination of Bio-Techne's content on CyVek's multiplex testing platform provides researchers with a powerful tool to develop, validate and test biomarker panels, so as to expedite life sciences research and enable biomarker-based diagnostics," said Per Hellsund, President and Chief Executive Officer of CyVek.

"We are very pleased to have formalized a strong working relationship with CyVek for the testing platform they have developed. We are confident that being able to deploy Bio-Techne's reagents on CyVek's innovative testing platform will translate into a powerful new solution for our customers. These features, in conjunction with the sample processing automation benefits of the CyVek technology, are sure to deliver valuable benefits to all users of this new technology. Additionally this is consistent with our long term strategy to expand Bio-Techne's business from being a reagent supplier to an applied-markets solutions provider," said Charles Kummeth, Bio-Techne's CEO.

---

## About Techne Corporation (d/b/a Bio-Techne)

Techne Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and clinical calibrators and controls. These activities are conducted through the Company's two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems has four subsidiaries: BiosPacific, Inc., located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, Bionostics, Inc., operating in Devens, Massachusetts, and R&D Systems China Co. Ltd., located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products. Bionostics is a leading supplier of control solutions used in point-of-care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation. Tocris is a leading supplier of chemical reagents for non-clinical life science research.

## Forward-Looking Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the Company's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "intend" or similar words. Such statements, including those relating to (i) the commitment to acquire CyVek if certain milestones are met, (ii) the commercial launch of CyVek's products, (iii) the benefits and prospects of CyVek's technology, and (iv) the Company's long-term strategy, involve risks and uncertainties that may affect actual results. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the success of CyVek's products and the actual financial results of CyVek, the ability of CyVek to meet future milestones, the satisfaction of other closing conditions to the acquisition of CyVek, the expected benefits of CyVek's technology on the Company's business and operations, the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

---

For additional information concerning such factors, see the section titled “Risk Factors” in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

#### About CyVek

CyVek is a privately funded biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. CyVek’s CyPlex™ is a versatile platform that can be quickly and easily configured for diverse applications, such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. For more information about CyVek, please call 203-679-0395 or visit us on the web at [www.cyvek.com](http://www.cyvek.com).

#### Bio-Techne Contact:

Charles Kummeth  
Chief Executive Officer  
(612) 379-8854